Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
| العنوان: | Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study |
|---|---|
| المؤلفون: | Beatrice Casadei, Lisa Argnani, Alessandro Broccoli, Caterina Patti, Piero Maria Stefani, Antonio Cuneo, Gloria Margiotta Casaluci, Carlo Visco, Guido Gini, Fabrizio Pane, Francesco D’Alò, Debora Luzi, Maria Cantonetti, Samantha Pozzi, Gerardo Musuraca, Chiara Rosignoli, Annalisa Arcari, Sofya Kovalchuk, Monica Tani, Maria Chiara Tisi, Mario Petrini, Vittorio Stefoni, Pier Luigi Zinzani |
| المساهمون: | Casadei B., Argnani L., Broccoli A., Patti C., Stefani P.M., Cuneo A., Casaluci G.M., Visco C., Gini G., Pane F., D'alo F., Luzi D., Cantonetti M., Pozzi S., Musuraca G., Rosignoli C., Arcari A., Kovalchuk S., Tani M., Tisi M.C., Petrini M., Stefoni V., Zinzani P.L. |
| المصدر: | Cancers, Vol 14, Iss 654, p 654 (2022) Cancers; Volume 14; Issue 3; Pages: 654 |
| بيانات النشر: | MDPI AG, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Idelalisib, Cancer Research, Refractory, Oncology, Idelalisib and folicular lymphoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Follicular lymphoma, Phosphatidylinositol 3-kinase inhibitor, Relapsed, follicular lymphoma, relapsed, refractory, idelalisib, phosphatidylinositol 3-kinase inhibitor, RC254-282 |
| الوصف: | Follicular lymphoma (FL) is an indolent hematological disease, often responsive to the first line of treatment, but characterized by repeated relapses. The therapeutic algorithm for relapsed/refractory FL patients comprises phosphatidylinositol 3-kinase inhibitors. Idelalisib showed anticancer activity, while inducing a significant rate of toxicities. Since the evidence in the literature on its use in normal clinical practice is scarce, a retrospective multicenter study was conducted to evaluate effectiveness and tolerability in a real-life context. Seventy-two patients with a median age at diagnosis of 57.2 years—mostly with an advanced stage (88.9%) and relapsed to the most recent therapy (79.1%)—were enrolled. The median number of prior therapies was three (20.8% refractory to the last therapy before idelalisib). With a median number of 4 months of treatment, the overall response rate was 41.7% (20.8% complete responses). Median disease-free survival and overall survival were achieved at 8.4 months and at 4 years, respectively. Forty-four percent of patients experienced at least one drug-related toxicity: 6.9% hematological ones and 43% non-hematological. The study confirmed that idelalisib has anticancer effectiveness and an acceptable safety profile in relapsed/refractory FL with unfavorable prognostic characteristics, even in the context of normal clinical practice. |
| وصف الملف: | application/pdf; ELETTRONICO |
| تدمد: | 2072-6694 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff1eb639b22d785174b8a2e72eee12f3Test https://doi.org/10.3390/cancers14030654Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....ff1eb639b22d785174b8a2e72eee12f3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726694 |
|---|